Skip to main content

Table 2 Non-BCMA-targeted CAR T clinical trials in multiple myeloma

From: Recent updates on CAR T clinical trials for multiple myeloma

NCT number (reference)

Target

Phase

Dosage

Number of patients

Responses

NCT02135406 (32)

CD19

1

1.1–6.0 × 108 CAR+T cells

10

VGPR: 6; PR: 2; PD: 2

NCT01886976 (34)

CD138

1/2

0.44–1.51 × 107 CAR+ T cells/kg

5

SD: 4; PD: 1

NCT00881920 (35)

κ light chain

1

0.2–2.0 × 108 CAR+ T cells/m2

16 (7 MM)

4 SD of 7 MM

  1. Abbreviations: BCMA B cell maturation antigen, CAR Chimeric antigen receptor, PD Progressive disease, PR Partial response, VGPR Very good partial response, SD Stable disease, MM Multiple myeloma